Orgenesis Inc. (NASDAQ:ORGS – Get Free Report) dropped 5.2% on Monday. The stock traded as low as $0.55 and last traded at $0.55. Approximately 100 shares changed hands during trading, a decline of 89% from the average session volume of 909 shares. The stock had previously closed at $0.58.
Orgenesis Stock Performance
The business has a 50 day simple moving average of $0.37 and a 200-day simple moving average of $0.37. The stock has a market capitalization of $1.81 million, a price-to-earnings ratio of -0.03 and a beta of 2.86.
Orgenesis Company Profile
Orgenesis Inc is a biotechnology company focused on developing and commercializing advanced cell and gene therapies. Its work centers on autologous cell therapies, which use a patient’s own cells, and on technologies intended to support the processing and manufacture of these therapies closer to the point of care.
The company’s platform includes its POCare ecosystem, which is designed to combine cell-therapy development, manufacturing, clinical applications and related data-management capabilities.
See Also
- Five stocks we like better than Orgenesis
- Could Velo3D Be the Next Defense Buyout Target?
- Penguin Solutions Is Soaring as AI Memory Demand Explodes
- Alphabet’s Chart Is Coiling—and the Fundamentals May Be Ready to Back It Up
- Morgan Stanley Is Bullish on Apple—But With a Catch
Receive News & Ratings for Orgenesis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Orgenesis and related companies with MarketBeat.com's FREE daily email newsletter.
